Comments
Drug-maker MSN Group has received approval for its Abbreviated New Drug Application (ANDA) Dimethyl Fumarate delayed release capsule.
Dimethyl Fumarate is a prescription medicine used to treat relapsing forms of multiple sclerosis in adults.
The active pharmaceutical ingredient and the finished formulation of Dimethyl Fumarate Delayed-Release Capsules are manufactured in-house at MSN’s facilities.
The Hyderabad-based MSN has entered into a commercial partnership with Dr Reddy’s for marketing the product in the US.
The medicine will be available in strengths of 120 mg and 240 mg capsules in bottle count sizes of 14 and 60 capsules, respectively.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.